ADC Therapeutics grants options for purchase of 109,800 common shares to new employees.

From GlobeNewswire: 2024-06-03 18:39:57

ADC Therapeutics SA (NYSE: ADCT) announced the allocation of options for the purchase of a total of 109,800 common shares to three new employees on June 3, 2024. This serves as a significant incentive for their employment and was approved by the company’s compensation committee. The options will vest on a yearly and monthly basis, becoming fully vested on the fourth anniversary, contingent on continued employment. ADC Therapeutics is a global leader in antibody-drug conjugates, with their CD19-targeting ADC ZYNLONTA receiving FDA accelerated approval for certain lymphoma treatments. The company is headquartered in Lausanne, Switzerland, with offices in London and New Jersey.

For more information, visit https://adctherapeutics.com/ and follow ADC Therapeutics on LinkedIn. ZYNLONTA® is a registered trademark of ADC Therapeutics SA.



Read more at GlobeNewswire: ADC Therapeutics gewährt neuen Mitarbeitern Zuteilungen im